Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course

Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is characterized by gradual cyst growth and expansion, increase in kidney volume with an ultimate decline in kidney function leading to end stage renal disease (ESRD). Given the...

Full description

Bibliographic Details
Main Authors: Kyoungmi Kim, Josephine F. Trott, Guimin Gao, Arlene Chapman, Robert H. Weiss
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Nephrology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12882-019-1249-6
_version_ 1819007387119386624
author Kyoungmi Kim
Josephine F. Trott
Guimin Gao
Arlene Chapman
Robert H. Weiss
author_facet Kyoungmi Kim
Josephine F. Trott
Guimin Gao
Arlene Chapman
Robert H. Weiss
author_sort Kyoungmi Kim
collection DOAJ
description Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is characterized by gradual cyst growth and expansion, increase in kidney volume with an ultimate decline in kidney function leading to end stage renal disease (ESRD). Given the decades long period of stable kidney function while cyst growth occurs, it is important to identify those patients who will progress to ESRD. Recent data from our and other laboratories have demonstrated that metabolic reprogramming may play a key role in cystic epithelial proliferation resulting in cyst growth in ADPKD. Height corrected total kidney volume (ht-TKV) accurately reflects cyst burden and predicts future loss of kidney function. We hypothesize that specific plasma metabolites will correlate with eGFR and ht-TKV early in ADPKD, both predictors of disease progression, potentially indicative of early physiologic derangements of renal disease severity. Methods To investigate the predictive role of plasma metabolites on eGFR and/or ht-TKV, we used a non-targeted GC-TOF/MS-based metabolomics approach on hypertensive ADPKD patients in the early course of their disease. Patient data was obtained from the HALT-A randomized clinical trial at baseline including estimated glomerular filtration rate (eGFR) and measured ht-TKV. To identify individual metabolites whose intensities are significantly correlated with eGFR and ht-TKV, association analyses were performed using linear regression with each metabolite signal level as the primary predictor variable and baseline eGFR and ht-TKV as the continuous outcomes of interest, while adjusting for covariates. Significance was determined by Storey’s false discovery rate (FDR) q-values to correct for multiple testing. Results Twelve metabolites significantly correlated with eGFR and two triglycerides significantly correlated with baseline ht-TKV at FDR q-value < 0.05. Specific significant metabolites, including pseudo-uridine, indole-3-lactate, uric acid, isothreonic acid, and creatinine, have been previously shown to accumulate in plasma and/or urine in both diabetic and cystic renal diseases with advanced renal insufficiency. Conclusions This study identifies metabolic derangements in early ADPKD which may be prognostic for ADPKD disease progression. Clinical trial HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A; Clinical www.clinicaltrials.gov identifier: NCT00283686; first posted January 30, 2006, last update posted March 19, 2015.
first_indexed 2024-12-21T00:23:46Z
format Article
id doaj.art-f32d0f4e5e9b47c0af299c4f920a2f76
institution Directory Open Access Journal
issn 1471-2369
language English
last_indexed 2024-12-21T00:23:46Z
publishDate 2019-02-01
publisher BMC
record_format Article
series BMC Nephrology
spelling doaj.art-f32d0f4e5e9b47c0af299c4f920a2f762022-12-21T19:22:03ZengBMCBMC Nephrology1471-23692019-02-0120111210.1186/s12882-019-1249-6Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease courseKyoungmi Kim0Josephine F. Trott1Guimin Gao2Arlene Chapman3Robert H. Weiss4Division of Biostatistics, Department of Public Health Sciences, University of CaliforniaDivision of Nephrology, Department of Internal Medicine, University of CaliforniaDepartment of Public Health Sciences, University of ChicagoNephrology Section, University of ChicagoDivision of Nephrology, Department of Internal Medicine, University of CaliforniaAbstract Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is characterized by gradual cyst growth and expansion, increase in kidney volume with an ultimate decline in kidney function leading to end stage renal disease (ESRD). Given the decades long period of stable kidney function while cyst growth occurs, it is important to identify those patients who will progress to ESRD. Recent data from our and other laboratories have demonstrated that metabolic reprogramming may play a key role in cystic epithelial proliferation resulting in cyst growth in ADPKD. Height corrected total kidney volume (ht-TKV) accurately reflects cyst burden and predicts future loss of kidney function. We hypothesize that specific plasma metabolites will correlate with eGFR and ht-TKV early in ADPKD, both predictors of disease progression, potentially indicative of early physiologic derangements of renal disease severity. Methods To investigate the predictive role of plasma metabolites on eGFR and/or ht-TKV, we used a non-targeted GC-TOF/MS-based metabolomics approach on hypertensive ADPKD patients in the early course of their disease. Patient data was obtained from the HALT-A randomized clinical trial at baseline including estimated glomerular filtration rate (eGFR) and measured ht-TKV. To identify individual metabolites whose intensities are significantly correlated with eGFR and ht-TKV, association analyses were performed using linear regression with each metabolite signal level as the primary predictor variable and baseline eGFR and ht-TKV as the continuous outcomes of interest, while adjusting for covariates. Significance was determined by Storey’s false discovery rate (FDR) q-values to correct for multiple testing. Results Twelve metabolites significantly correlated with eGFR and two triglycerides significantly correlated with baseline ht-TKV at FDR q-value < 0.05. Specific significant metabolites, including pseudo-uridine, indole-3-lactate, uric acid, isothreonic acid, and creatinine, have been previously shown to accumulate in plasma and/or urine in both diabetic and cystic renal diseases with advanced renal insufficiency. Conclusions This study identifies metabolic derangements in early ADPKD which may be prognostic for ADPKD disease progression. Clinical trial HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A; Clinical www.clinicaltrials.gov identifier: NCT00283686; first posted January 30, 2006, last update posted March 19, 2015.http://link.springer.com/article/10.1186/s12882-019-1249-6ADPKDMetabolomicsProgressionHALT study
spellingShingle Kyoungmi Kim
Josephine F. Trott
Guimin Gao
Arlene Chapman
Robert H. Weiss
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
BMC Nephrology
ADPKD
Metabolomics
Progression
HALT study
title Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
title_full Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
title_fullStr Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
title_full_unstemmed Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
title_short Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course
title_sort plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive adpkd patients early in the disease course
topic ADPKD
Metabolomics
Progression
HALT study
url http://link.springer.com/article/10.1186/s12882-019-1249-6
work_keys_str_mv AT kyoungmikim plasmametabolitesandlipidsassociatewithkidneyfunctionandkidneyvolumeinhypertensiveadpkdpatientsearlyinthediseasecourse
AT josephineftrott plasmametabolitesandlipidsassociatewithkidneyfunctionandkidneyvolumeinhypertensiveadpkdpatientsearlyinthediseasecourse
AT guimingao plasmametabolitesandlipidsassociatewithkidneyfunctionandkidneyvolumeinhypertensiveadpkdpatientsearlyinthediseasecourse
AT arlenechapman plasmametabolitesandlipidsassociatewithkidneyfunctionandkidneyvolumeinhypertensiveadpkdpatientsearlyinthediseasecourse
AT roberthweiss plasmametabolitesandlipidsassociatewithkidneyfunctionandkidneyvolumeinhypertensiveadpkdpatientsearlyinthediseasecourse